A real-world evidence study evaluating Geffer effervescent granules for the symptomatic relief of digestive symptoms

Matteo Alemanni; Raffaella de Salvo; Barbara Moroni; Andreas Ehret

doi:10.1177/20503121221088815

A real-world evidence study evaluating Geffer effervescent granules for the symptomatic relief of digestive symptoms

SAGE Open Med. 2022 Mar 29:10:20503121221088815. doi: 10.1177/20503121221088815. eCollection 2022.

Authors

Matteo Alemanni¹, Raffaella de Salvo², Barbara Moroni¹, Andreas Ehret²

Affiliations

¹ Bayer S.p.A., Milano, Italia.
² Bayer Consumer Care AG, Basel, Switzerland.

Abstract

Objectives: Geffer effervescent granules (active ingredients: metoclopramide, dimethicone, and sodium bicarbonate) is an established over-the-counter medication available in Italy for the symptomatic treatment of hyperacidity (pain and/or heartburn) when accompanied by slowing of gastric transit, nausea, aerophagia, and bloating, all symptoms that can occur in functional dyspepsia and can negatively impact individuals' quality of life. The aim of this observational study was to explore the perceived benefits of, and consumer experience with, Geffer effervescent granules used for the symptomatic treatment of digestive disorders suggestive of functional dyspepsia under real-life conditions in Italy.

Methods: Adults (aged 35-65 years) experiencing symptoms suggestive of functional dyspepsia/indigestion at least once a month and who had used Geffer effervescent granules within the previous 6 months completed an online questionnaire eliciting information on symptom relief (speed of onset and duration) and quality of life.

Results: Geffer effervescent granules provided rapid onset of symptom relief, with 21% of respondents perceiving an effect within 10 min and 88% reporting an improvement in overall symptoms within 30 min. A similarly rapid onset of complete resolution of gastric pain/cramps, acidity, bloating, nausea, and bothersome fullness symptoms was reported by 65%-83% of respondents; 50%-59% of respondents were free from such symptoms for more than 3 h or until the next meal. Most participants (92%) reported that their quality of life improved when taking Geffer effervescent granules to treat hyperacidity symptoms. Overall, 95% of the respondents were satisfied with the effectiveness of Geffer effervescent granules on overall symptom relief.

Conclusions: In Italian consumers with digestive disorders likely due to functional dyspepsia, Geffer effervescent granules was associated with rapid, complete, and durable relief of symptoms of gastric pain/cramps, acidity, bloating, nausea, and bothersome fullness; an improvement in quality of life; and a high level of consumer satisfaction.

Keywords: Gastroenterology/hepatology; efficacy; functional dyspepsia; quality of life; real world evidence.